For Our Patients
Clinical Trials and Research
Enrolling in
a Study
Thank you for your interest in enrolling in one of our studies.
New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.
Currently Enrolling Studies
New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.
The following studies are currently available for enrollment.
For Central Florida Patients
Annexon
Study/Protocol Number: ANX007-GA-02 (Archer II)
Title: A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Ocular wAMD
Title: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Oculis Diamond for DME
Title: Phase 2/3 double masked, Randomized, stage 2 Multicenter study of the Efficacy and Safety of OCS-01- Eye. Drops in Subjects with Diabetic Macular Edema
RGX-314-3101 for the treatment of w AMD
Protocol Title: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Stealth Dry AMD
Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (AMD) with Photoreceptor Loss
Outlook (Norse Eight) Wet AMD treatment naïve
Recomninant, humanized, anti-human vascular endothelial growth factor monoclonal antibody, administered at a dose of 1.25 by intravitreal injection.
Active Studies but Closed for Enrollment
Aviceda GA secondary to AMD
QUASAR - Retinal Vein Occlusions
ASCENT - Wet Macular Degeneration
ELEVATUM - Diabetic Macular Edema
SHANGHAI HENLIUS for Wet Age-Related Macular Degeneration
New Day is for Diabetic Macula EDEMA
Pulsar WET MACULAR DEGENERATION
For North Florida Patients
ANX007-GA-02 – Geographic Atrophy
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled study of the Efficacy, safety, and tolerability of ANX007 Administered by Intravitreal Injection in patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Crimson / BI-1436-0007
A multicentre, randomized, sham-controlled, double masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
KDK-1101-02
A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO) – GION-
F. Hoffmann-La Roche Ltd-RIVOL1-CRVO BP44241
A PHASE Ib, multicenter, randomized, double masked, active comparator-controlled study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200394 in participants with macular edema secondary to central retinal vein occlusion.
DRCR-Protocol AF- Non-Proliferative Diabetic Retinopathy
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.
DRCR-Protocol AO- Home OCT vs Treat and Extend Study
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
Active Studies but Closed for Enrollment
Norse Eight Wet AMD
Pulsar WET MACULAR DEGENERATION
SHANGHAI HENLIUS FOR WET AMD
DRCR- Protocol AM- Epiretinal Membranes
Genentech, Inc – Magic ML43601- NPDR
ONL Therapeutics, Inc. (Retinal Detachment)
DRCR-Protocol AJ- Macula Hole
For more information about clinical trials or if you should have any questions, please feel free to contact us.
